NO20060964L - Farmasoytiske sammensetninger med midifisert frigjoring av modafinil - Google Patents

Farmasoytiske sammensetninger med midifisert frigjoring av modafinil

Info

Publication number
NO20060964L
NO20060964L NO20060964A NO20060964A NO20060964L NO 20060964 L NO20060964 L NO 20060964L NO 20060964 A NO20060964 A NO 20060964A NO 20060964 A NO20060964 A NO 20060964A NO 20060964 L NO20060964 L NO 20060964L
Authority
NO
Norway
Prior art keywords
modafinil
pharmaceutical compositions
modified release
pharmaceutical
traditional
Prior art date
Application number
NO20060964A
Other languages
English (en)
Norwegian (no)
Inventor
Piyush R Patel
Alpa Parikh
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34381093&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20060964(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of NO20060964L publication Critical patent/NO20060964L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
NO20060964A 2003-09-18 2006-02-28 Farmasoytiske sammensetninger med midifisert frigjoring av modafinil NO20060964L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50402803P 2003-09-18 2003-09-18
US10/944,528 US8153159B2 (en) 2003-09-18 2004-09-17 Modafinil modified release pharmaceutical compositions
PCT/US2004/030815 WO2005027890A1 (en) 2003-09-18 2004-09-20 Modafinil modified release pharmaceutical compositions

Publications (1)

Publication Number Publication Date
NO20060964L true NO20060964L (no) 2006-04-18

Family

ID=34381093

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060964A NO20060964L (no) 2003-09-18 2006-02-28 Farmasoytiske sammensetninger med midifisert frigjoring av modafinil

Country Status (20)

Country Link
US (1) US8153159B2 (enExample)
EP (1) EP1670447B1 (enExample)
JP (1) JP5138932B2 (enExample)
KR (1) KR20060117910A (enExample)
AR (1) AR046410A1 (enExample)
AT (1) ATE448780T1 (enExample)
AU (1) AU2004274017B2 (enExample)
BR (1) BRPI0414299A (enExample)
CA (1) CA2536666C (enExample)
DE (1) DE602004024220D1 (enExample)
EA (1) EA011400B1 (enExample)
ES (1) ES2336215T3 (enExample)
IL (1) IL173738A (enExample)
IS (1) IS2787B (enExample)
MX (1) MXPA06003125A (enExample)
MY (1) MY144755A (enExample)
NO (1) NO20060964L (enExample)
NZ (1) NZ545573A (enExample)
TW (1) TWI344840B (enExample)
WO (1) WO2005027890A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01004381A (es) * 1998-11-02 2005-09-08 Elan Corp Plc Composicion de multiparticulado de liberacion modificada.
EP1755388B1 (en) 2004-05-28 2010-10-06 Transform Pharmaceuticals, Inc. Mixed co-crystals and pharmaceutical compositions comprising the same
WO2006063078A2 (en) * 2004-12-08 2006-06-15 Elan Corporation, Plc Topiramate pharmaceuticals composition
WO2007037790A2 (en) * 2005-06-08 2007-04-05 Elan Corporation, Plc Modified release famciclovir compositions
CA2642275A1 (en) 2006-02-13 2007-08-23 Vanda Pharmaceuticals, Inc. Stable dosage formulations of imidazolylalkyl-pyridines
AU2007272501A1 (en) * 2006-07-12 2008-01-17 Elan Pharma International Limited Nanoparticulate formulations of modafinil
DE102006035549A1 (de) 2006-07-27 2008-01-31 Evonik Röhm Gmbh Arzneiform mit mindestens zweischichtiger Trennschicht
US20090082461A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched modafinil
JP5250285B2 (ja) * 2008-03-26 2013-07-31 富士フイルム株式会社 経口物用被覆材、可食性容器およびそれらを用いた経口物
WO2010012407A1 (en) * 2008-07-29 2010-02-04 Ashland Licensing And Intellectual Property Llc. Modified additives for suppressing dust formation
MX2013000001A (es) * 2010-07-06 2013-05-01 Navipharm Co Ltd Composición farmaceutica de liberacion prolongada y acción retardada que comprende dapoxetina para administaracion oral.
US8999393B1 (en) * 2013-01-09 2015-04-07 Edgemont Pharmaceuticals Llc Sustained release formulations of lorazepam
MX2016014320A (es) 2014-05-01 2017-05-23 Sun Pharmaceutical Ind Ltd Composiciones de suspension de liberacion prolongada.
ES3008933T3 (en) 2015-09-29 2025-03-25 Merz Pharmaceuticals Llc Sustained release compositions of 4-aminopyridine
TWI838340B (zh) * 2017-07-10 2024-04-11 日商武田藥品工業股份有限公司 含有沃諾拉贊的製劑

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534263A (en) * 1995-02-24 1996-07-09 Alza Corporation Active agent dosage form comprising a matrix and at least two insoluble bands
US6346548B1 (en) * 1999-08-16 2002-02-12 Cephalon, Inc. Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6458384B2 (en) * 2000-02-23 2002-10-01 Impetus Ag Pharmaceutical with predetermined activity profile
US6492396B2 (en) 2000-05-16 2002-12-10 Cephalon, Inc. Substituted thioacetamides
US6489363B2 (en) * 2000-10-11 2002-12-03 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
US6344215B1 (en) * 2000-10-27 2002-02-05 Eurand America, Inc. Methylphenidate modified release formulations
US7141555B2 (en) 2000-12-19 2006-11-28 Cephalon, Inc. Modafinil compound and cyclodextrin mixtures
US7297346B2 (en) 2001-05-25 2007-11-20 Cephalon Inc. Pharmaceutical formulations of modafinil
GB0117618D0 (en) 2001-07-19 2001-09-12 Phoqus Ltd Pharmaceutical dosage form
US7229644B2 (en) * 2002-05-23 2007-06-12 Cephalon, Inc. Pharmaceutical formulations of modafinil
US20040116532A1 (en) 2002-09-13 2004-06-17 Craig Heacock Pharmaceutical formulations of modafinil

Also Published As

Publication number Publication date
ATE448780T1 (de) 2009-12-15
WO2005027890A1 (en) 2005-03-31
IL173738A0 (en) 2006-07-05
ES2336215T3 (es) 2010-04-09
IS2787B (is) 2012-06-15
CA2536666A1 (en) 2005-03-31
TWI344840B (en) 2011-07-11
EA011400B1 (ru) 2009-02-27
AU2004274017A1 (en) 2005-03-31
JP2007518696A (ja) 2007-07-12
IS8327A (is) 2006-02-23
EA200600590A1 (ru) 2006-08-25
AR046410A1 (es) 2005-12-07
CA2536666C (en) 2012-06-19
BRPI0414299A (pt) 2006-11-14
KR20060117910A (ko) 2006-11-17
EP1670447B1 (en) 2009-11-18
MXPA06003125A (es) 2006-06-20
HK1089697A1 (en) 2006-12-08
US8153159B2 (en) 2012-04-10
NZ545573A (en) 2010-02-26
US20050095294A1 (en) 2005-05-05
MY144755A (en) 2011-10-31
AU2004274017B2 (en) 2010-07-08
TW200520748A (en) 2005-07-01
EP1670447A1 (en) 2006-06-21
IL173738A (en) 2012-07-31
DE602004024220D1 (de) 2009-12-31
JP5138932B2 (ja) 2013-02-06

Similar Documents

Publication Publication Date Title
NO20060964L (no) Farmasoytiske sammensetninger med midifisert frigjoring av modafinil
DK3219705T3 (da) Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid
HRP20080564T3 (hr) Dihidrotetrabenazini i farmaceutski pripravci koji ih sadrže
DK1206474T3 (da) Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer
LTPA2018502I1 (lt) Per burną vartojamos kladribino kompozicijos
NO20052058D0 (no) Behandling av influensa.
NO20071078L (no) Antivirale forbindelser
NO20070866L (no) Antivirale forbindelser.
WO2005000860A3 (en) Compositions and methods for treatment of disease with acetylated disaccharides
NO20082547L (no) Orale formuleringer omfattende tigecycline
NO20033618D0 (no) Ftalayinon-piperidino-derivater som PDE-4-inhibitorer
CL2007001838A1 (es) Compuestos derivados de 4-oxoquinolina; composicion farmaceutica; y uso del compuesto para la produccion de un agente anti-vih.
NO20044916L (no) Preparater av sulfinylacetamid
CL2007002380A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica.
NO20051281D0 (no) Sammensetning for anrikning av naeringsmidler
NO20043937L (no) Anvendelse av vitamin D sammensetninger
DK1458413T3 (da) Farmaceutiske sammensætninger på b asis af azetidin-derivater
IS6960A (is) Fenýl heterósýklýl eter afleiður sem serótónín endurupptökuhindrar
NO20042640L (no) Fremgangsmate for fremstilling av ekinocandinderivater
DK1475379T3 (da) Anvendelse af scopinesterderivater til fremstilling af lægemidler
EA200300727A1 (ru) Производные 2h-1-бензопирана, способы их получения и их фармацевтические композиции
DK1687297T3 (da) Triazindimerer til behandling af autoimmunsygdomme
DK1658062T3 (da) Alfa-aminoamid-derivater anvendelige som anti-inflammatoriske midler
NO20052471D0 (no) Fremgangsmate for fremstilling av 3-metyltiopropanal.
ATE450273T1 (de) Proliferationshemmendes arzneimittel

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application